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Radiotherapy omission after lumpectomy is a reasonable option for many older women with 
favorable prognosis breast cancer. We sought to evaluate patient perspectives regarding 
decision-making about radiotherapy (RT).   
 
Methods 
Women age 65-79 with stage I and II breast cancer reported to the Georgia and Los Angeles 
County SEER registries were surveyed (response rate=70%) regarding radiotherapy decisions, 
the rationale for omitting RT, decision-making values, and understanding of recurrence risk. We 
also surveyed their corresponding surgeons (response rate=77%). We evaluated patient 
characteristics associated with omission of RT using multilevel, multivariable logistic regression, 
accounting for patient clustering within surgeons.  
 
Results 
Of 999 patients, 135 omitted RT (14%). Older age, lower grade, and estrogen receptor-positive 
disease were each strongly associated with omission of RT in multivariable analyses, whereas 
number of comorbidities was not. Non-English speakers were more likely to omit RT (adjusted 
OR 5.9, 95% CI 1.4-24.5).  
 
The most commonly reported reasons for RT omission were that a physician advised the patient 
it was not needed (54% of patients who omitted RT) and patient choice (41%). Local recurrence 
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risk was overestimated by all patients, by about 2-fold among those who omitted radiation and 
8-fold among those who received radiotherapy. Distant disease recurrence risk was 
overestimated 3-fold on average.  
 
Conclusions 
To some extent, decisions about radiotherapy omission are appropriately influenced by age, 
grade, and estrogen receptor status, but do not appear to be optimally tailored according to 
competing comorbidities. Many women who are candidates for radiotherapy omission 
overestimate their risk of recurrence.  
 
Condensed Abstract: (2 concise sentences) 
Radiotherapy omission among older women with early stage breast cancer was appropriately 
associated with age, grade, and estrogen receptor status, but did not appear to be tailored 
according to comorbid disease. Despite their favorable prognosis, many older women with 
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There is growing concern about overtreatment in older women with early stage breast cancer 
because they are often more likely to die of competing comorbidities than breast cance.1 Two 
trials (CALGB 9343 and PRIME II) have shown that among older women with stage I, estrogen 
receptor (ER)-positive invasive breast cancer that is treated with breast conserving surgery and 
endocrine therapy, adjuvant radiotherapy significantly reduces the incidence of local 
recurrence, but without an apparent influence on the rate of metastasis or breast cancer 
mortality.2, 3 Guidelines now consider omission of RT after BCS as an acceptable treatment 
option for women age ≥70 with stage T1, clinically node negative, ER-positive breast cancer 
who receive endocrine therapy.4 
 
Some have argued that all older women with characteristics similar to the eligibility 
requirements for CALGB 9343 and PRIME II should not receive radiotherapy, whether infirm or 
fit.5 Others have advocated for a more individualized approach to decisions about RT that 
accounts for tumor characteristics, comorbidity, and patient preferences.3 The lack of 
consensus regarding the treatment approach in this scenario is evident in several practice 
patterns studies that revealed only a modest decline in RT utilization after publication of CALGB 
9343 results.6-10 Our previous work evaluating clinician views on radiotherapy omission in this 
context found that many clinicians overestimate the benefits associated with radiotherapy and 
continue to consider RT omission to be substandard therapy.11The frequency with which older 
patients are offered treatment without RT is uncertain, and little is known about their 
understanding of the risks and benefits of this treatment approach. 
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In this setting of evolving views on the treatment paradigm for older women with favorable 
prognosis breast cancer, we sought to evaluate patients’ perspectives on the decision about 
radiotherapy omission as part of a survey that included a sizable sample of older women 
recently diagnosed with early stage breast cancer, as identified by the population-based 
Georgia and Los Angeles SEER registries. To our knowledge, this is the first study to evaluate 
patient views on radiotherapy omission. Our objectives were 1) to evaluate patient 
characteristics associated with radiotherapy omission; 2) explore patients’ rationale for not 
receiving radiotherapy; and 3) assess patients’ understanding of recurrence risk.   
 
Methods 
Patient Sample and Data Collection 
The Individualized Cancer Care (iCanCare) Study is a large survey study of women with early-
stage breast cancer between age 20-79 years who were reported to the population-based 
Surveillance, Epidemiology and End Results (SEER) registries of Los Angeles County, California 
and Georgia. Racial minorities were oversampled. Patients with tumors larger than 5cm or 
stage III to IV disease were excluded. From the iCanCare study, we selected women age ≥65 for 
the present analysis. 
 
Between July 2013 and August 2015, we identified 7,303 women who were confirmed to be 
eligible for the study. Surveys were completed a median of 6.8 months (SD 3.2) after diagnosis, 
with a response rate of 69.6% (n = 5080). The analytic sample (n=999) for the present study 
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consisted of patients age 65-79 with unilateral invasive breast cancer treated with breast 
conserving surgery (online supplementary figure 1). Within this sample, 74% of patients had 
stage I disease and 23% stage II (table 1). Given that we observed a non-negligible rate of 
radiotherapy omission in stage II patients (12%), we also included stage II patients in 
multivariable models of radiotherapy omission.  
 
Surveys were mailed with a $20 cash incentive; a modified Dillman method was used to 
improve the response rate.12 Materials were mailed in English; Spanish-translated materials 
were added for women with surnames that suggested Hispanic ethnicity.13 Each SEER registry 
provided SEER data that were stripped of identifiers and merged to survey data. This study was 
approved by the University of Michigan Institutional Review Board, the University of Southern 
California, Emory University, and the public health departments of Georgia and California.  
 
Measures 
We developed the questionnaire iteratively with input from survey design experts and cognitive 
interviews with patients and clinicians to assess content validity, as described previously.14  
 
The definitive surgical procedure was determined by asking patients to indicate the surgery that 
was performed after biopsy, and whether additional surgeries were performed. As the primary 
outcome measure, radiotherapy receipt was determined by asking patients, “Did you or are you 
planning to have radiation therapy to treat your breast cancer?” as well as whether 
radiotherapy (RT) was completed, ongoing, or planned. Information on endocrine therapy 
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receipt was available for 62% of the analytic sample (n=619) who completed the survey module 
on endocrine therapy. 
 
Patient preferences and values were assessed by asking, “When decisions were being made 
about your treatments, how important was it to you that your treatments…” followed by 
several prompts (detailed in figure 4),  such as, “kept you from worrying about the cancer 
coming back,” each rated on a 5 point Likert-type scale ranging from “not at all important” to 
“very important.” Women who omitted radiotherapy were asked to indicate the reasons for 
their decision in a “mark all that apply” format. Responses were aggregated into higher (i.e. a 
lot, quite a bit, or somewhat) and lower (i.e. not at all or a little bit) categories for analysis. 
 
We evaluated patient perceptions of recurrence risk by asking, “After receiving all the planned 
treatments, what do you think is the chance that your cancer will come back in the breast or 
the area around it within 10 years?” with instructions to write in a number from 0% to 100%. A 
similar question was asked about “the chance that your cancer will spread to other parts of 
your body within 10 years.” We asked patients how often they had worried about their cancer 
coming back within the past month, with responses on a 5-point scale ranging from “almost 
never” to “almost always,” dichotomizing those who reported “sometimes,” “often,” or “almost 
always” worrying from those reporting worrying “rarely” or “almost never.” We asked how 
much doctors discussed the chance of cancer recurrence, ranging from “not at all” to “a lot” on 
a 5-point scale. Patients’ decision control preferences were evaluated by asking if they 
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“preferred to make [their] own decisions,” with responses as “quite a bit of the time” or “all of 
the time” dichotomized from “some of the time,” “a little of the time,” and “none of the time.”  
 
Additional covariates included patient-reported information on comorbidities, race/ethnicity 
(white, black, Asian, Latina, other), education (no college vs at least some college), income 
(<$20, $20-40, $40-60, $60-90, >$90, in thousands), insurance (private, Medicare, Medicaid, 
other), marital status (married, divorced/separated, never married, widowed), and travel time 
to the nearest radiation oncology facility (<15, 15-30, 31-60, >60 minutes). We asked patients 
to indicate which language they primarily speak.  
 
Surgeon Sample and Data Collection 
Patients were asked to identify their surgeons. From the patient analytic sample, 960 women 
were linked to 311 treating surgeons, of whom 240 completed a surgeon-specific survey (77%). 
A mean of 3 patients (IQR 1-4) were linked to each surgeon. Surgeons were asked about their 
annual breast cancer patient volume, whether the practice included residents and fellows, and 
number of years in practice. Surgeons were also asked, “How involved are you in the selection 
of adjuvant radiation therapy approach in your post-lumpectomy patients?” with answers 
ranging from “not at all involved” to “very involved” on a 5-point scale. 
 
Statistical Analysis. We first calculated the proportion of women omitting radiotherapy overall 
and by all demographic and treatment factors.  Bivariate associations with radiotherapy 
omission were evaluated using the Rao-Scott χ2 test.  Multivariable, multilevel logistic 
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regression was used to explore the adjusted associations with radiotherapy omission, with 
patients as the primary units of observation and the surgeon identifiers as the secondary units 
(i.e. patients clustered within surgeon) 15.  Models were constructed beginning with patient-
level covariates, incorporating surgeon clustering, and finally adding surgeon-level covariates.  
Area under the receiver-operator curve (AUC) was reported to measure the model’s 
discriminatory ability.  All statistical analyses incorporated weights to account for the 
differential probability of sample selection and survey nonresponse.  Additionally, though 
survey and SEER item nonresponse was low (<5%) for most covariates, we multiply imputed 
missing items using sequential multiple imputation techniques14, 16 to prevent potential bias 
when using complete-case methods in the presence of missing data.  P-values 5% or less were 
considered significant throughout. All analyses were conducted using the SAS system version 





Table 1 and online supplementary table 1 show the distribution of patient and surgeon 
characteristics. Overall, 14.4% of women in this sample of older women omitted radiotherapy 
after breast conserving surgery, with 15.7% omission in the subset of patients with ER+, Stage I 
disease. Among those who received radiotherapy, 48.1% received conventionally fractionated 
whole breast RT, 26.6% received hypofractionated whole breast RT, 11% received accelerated 
partial breast RT, 2.2% reported “other” or the duration was not specified, and 12.1% were 
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scheduled to receive RT but had not yet received it at the time of survey. On bivariate analysis, 
age, grade, ER status, SEER region, and income were associated with RT omission. Figure 1 
shows the results of a multilevel logistic regression model that includes patient-level variables, 
SEER site, and surgeon identity. Older patient age, lower grade, and ER-positive disease were 
each strongly correlated with RT omission. Age 75-79 had a dominant effect, with an odds ratio 
of 14.4 (95% CI 5.6-37.1) when compared to age 65-69. The odds of non-English speakers 
omitting RT were greater when compared to English speakers (OR 5.9, 95% CI 1.4-24.5). It is 
noteworthy that patient comorbidities were not associated with RT omission on either 
bivariable or multivariable analysis (OR 1.3 for ≥2 vs 0 comorbidities, 95% CI: 0.6-2.9). Surgeon 
variables were not significantly associated with radiotherapy omission and were therefore not 
retained in the final model.  
 
The multilevel model predicted RT omission well, with an AUC of 0.83 (95% CI 0.79-0.87). When 
analyzing clustering according to the surgeon identifier, the odds of a patient omitting 
radiotherapy would be predicted to increase approximately two-fold (OR 1.83, 95% CI 0.87-
3.87) if she were to see a surgeon with a practice approach one standard deviation above the 
RT omission rate of an average surgeon (while adjusting for other model covariates). However, 
this trend for surgeon influence was not statistically significant. In a model restricted to the 
subgroup of patients with information on hormonal therapy, use of endocrine therapy was not 
significantly associated with radiotherapy omission, although there appeared to be a trend for 
women who omit radiotherapy to also omit endocrine therapy (OR 2.22, 95% CI 0.87-5.65; data 
not shown). In a model limited to patients with ER+, stage I disease, we again observed that 
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age, grade, and non-English speakers were significantly correlated with radiotherapy omission, 
without significant association with comorbidities, similar to the model derived from the larger 
analytic sample.   
 
Risk Perception and Communication 
In the subset of patients with ER+, Stage I disease, 33.1% of women overestimated their risk of 
local recurrence after all treatments were received as being >10% at 10 years.  Among those 
who omitted RT, when asked to approximate their risk of local recurrence at 10 years, the mean 
estimate was 19% at 10 years (compared to the CALGB finding of 10%), and among women who 
received RT, the mean estimate was 17% (in contrast to CALGB 9343 finding of 2%; figure 2).2 
The risk of distant disease recurrence risk was similarly overestimated, with 46% of women 
approximating their risk of distant recurrence as being >5% at 10 years. The mean estimate of 
10-year distant recurrence risk was 16.0% (compared to the CALGB finding of 5% both among 
those who received and omitted RT).2 In this group of older women with favorable prognosis, 
approximately a quarter (26.9%) reported that within the last month, they had “sometimes,” 
“often,” or “almost always” worried about their cancer coming back, without significant 
differences for women who received or omitted RT.  
 
Regarding communication with providers, 46.2% of patients in the overall sample reported that 
their physicians used numeric estimates to describe the risk of the cancer coming back. 
Approximately one-third (37.9%) reported that their doctors discussed the chance of the cancer 
coming back “not at all” or “a little bit.” Although the majority of women (70.0%) reported that 
Page 12 of 51Cancer











they preferred that their doctors tell them what to do for breast cancer treatment, women who 
omitted radiotherapy were more likely to report that they preferred to make their own 
decisions about breast cancer treatments than women who received RT (45.8% vs 35.7%, 
p=0.03).  
 
Patient Preferences and Values 
Among women who omitted radiotherapy, the most commonly reported reasons were that a 
physician told the patient it was not needed (53.8% of patients who omitted RT) and that the 
decision was left to the patient and she chose to omit RT (40.9%, figure 3). Concerns about 
placing an excessive burden on family and absence of discussion with a doctor about RT were 
uncommon reasons for omitting RT (≤5%). Although 11.8% of patients reported “quite a bit” or 
“a lot” of worry about current or future financial problems as a result of breast cancer and 
treatments, <1% of women who omitted radiotherapy reported that cost motivated their 
treatment decision.  
 
When asked about considerations that were important in their decision-making, the most 
commonly reported priorities were that the treatment kept them from worrying about the 
cancer coming back (74.0%), had a low possibility of complications (73.9%), and allowed them 
to continue caring for their home and family (73.6%, figure 4). Women who omitted 
radiotherapy more commonly endorsed the importance of avoiding exposure to radiation (69% 
vs 37%, p<0.001) and the need for fewer trips for treatment visits (49.2% vs 37.2%, p=0.008).  
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In this large, contemporary survey of older women with early stage breast cancer, we observed 
that to a substantial extent, decisions about radiotherapy omission appear to be appropriately 
tailored based on older age, ER-positive disease, and lower grade tumor. However, the higher 
rate of RT omission in non-English speakers and the lack of association with comorbidity 
observed here are concerning. Incorporation of age and pathology findings into the decision to 
omit RT may be viewed as a starting point, but there remains a great need to further consider 
comorbidity status and remaining life expectancy to ensure that decisions about radiotherapy 
are appropriately individualized.17  
 
We found that despite having an excellent prognosis, a sizeable proportion of older women 
with Stage I, ER+ breast cancer overestimate their risk of local recurrence, with an average two-
fold overestimation in women who omitted RT and 8-fold overestimation in women who 
received RT. Nearly half of women perceived that their risk of distant recurrence was higher 
than has been reported in clinical trials, with an average 3-fold overestimation. This 
unrealistically pessimistic view of recurrence risk is reflected in the report from a quarter of 
women that they had frequently worried about cancer recurrence within the preceding month.  
Our observations are consistent with prior reports that notwithstanding a favorable prognosis, 
a large proportion of the most favorable subgroup in our sample of older women felt they were 
likely to develop a local or distant recurrence and die from breast cancer, resulting in 
psychological distress, frequent worry, and lower quality of life.18, 19 Overestimation of 
recurrence risk may lead to a multiplicative overestimation of risk reduction from 
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interventions,20 resulting in overly generous attribution of benefits obtained from treatment. 
This might underlie the correlation that has been observed between worry about recurrence 
and receipt of radiotherapy in prior research.21, 22 It is notable that one of the highest priorities 
that influenced decision-making for women in our study was that the treatment minimize the 
worry about cancer recurrence. Although radiotherapy undoubtedly does reduce the risk of 
local recurrence,2, 3 our results indicate a need to more clearly communicate the favorable 
prognosis in this group, and to more directly address worry about recurrence and ensure that 
decisions are optimally informed.  
 
The effects of patient overestimation of recurrence risk may well relate to physician 
overestimation that has been demonstrated in other work. In a nationwide survey, 19% of 
radiation oncologists and 32% of surgeons overestimated the 10-year risk of local recurrence.11  
The reluctance of many surgeons and radiation oncologists to consider radiotherapy omission 
to be a reasonable option in select older women is particularly problematic given the findings of 
the current study demonstrating that the most common reason given by women for the 
decision to omit radiotherapy was advice from a doctor that radiotherapy was not needed. 
Furthermore, most women (70%) preferred that their doctors tell them what to do regarding 
their breast cancer treatment.  Therefore, physicians’ attitudes and approaches to 
communication may be particularly important to ensure that patients do indeed consider all 
options and their risks and benefits.  Many potential mechanisms have been considered as 
possible drivers of physicians’ poor communication practices in this setting, including lack of up-
to-date knowledge of clinical trial results,23 heuristics like risk aversion and anticipatory regret 
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that may motivate physicians and patients alike to embrace overly aggressive treatments,24 lack 
of training in effective risk communication skills,25 and financial incentives that reimburse the 
delivery of care rather than its omission.7  Our data suggest a compelling need to evaluate the 
relative roles of these underlying drivers further in order to develop appropriately targeted 
interventions that encourage clinicians to improve communication in this regard.  We find it 
striking that one-third of women reported minimal discussions with their providers about the 
risk of recurrence, which is absolutely essential for a patient to understand the relative impact 
of interventions like radiotherapy.  
 
Our data suggest that surgeons, who are the first breast cancer clinicians to outline a plan of 
care, may play an important role in decisions regarding radiotherapy omission.  Although we 
did not detect a statistically significant impact of the surgeon on the likelihood of radiotherapy 
omission, this may be due to the sample size and distribution of patients across surgeons within 
our sample. We did, however, observe a notable trend, and others have shown that among 
women with short life expectancy, the probability of receiving RT varies substantially across 
primary surgeons.26   
 
We also found that non-English speakers were significantly more likely to omit radiotherapy, 
even after adjustment for race, income, employment and education.  This finding may reflect 
barriers to high quality decision-making in a vulnerable population. Numerous reports describe 
non-English speakers as a vulnerable population, particularly Latinas with low acculturation.27-30 
Latina women who are less acculturated have previously been found to have greater desire for 
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information, lower satisfaction with breast cancer decision-making,30 and perceived 
powerlessness in medical encounters,31 highlighting a need for greater attention to support 
these patients and identify potential barriers.32 Although disparities are often viewed in the 
context of undertreatment of an aggressive cancer, with vulnerability related to known risk 
factors such as lower education or minority race, it is interesting to note that vulnerability to 
overtreatment may be an entirely distinct concept that primarily affects classically privileged 
populations, as has been observed with trends in contralateral prophylactic mastectomy.33, 34 
The association between language barrier and RT omission is worthy of further exploration in 
future studies.  
  
We observed a trend for patients who omit radiotherapy to also omit endocrine therapy. This is 
a particularly concerning finding that merits further evaluation, as receipt of endocrine therapy 
is known to have a substantial impact in reducing local recurrence35 and is believed to be a key 
factor in leading to the acceptable rates of local failure observed in trials like CALGB 9343 as 
compared to historical studies where endocrine therapy was not required.36, 37   Endocrine 
therapy non-adherence and discontinuation are known to be an issue for nearly half of women 
with breast cancer in general,38  and if women who omit radiotherapy are even more likely to 
omit endocrine therapy, rates of recurrence may be higher than expected.  
 
Aspects of the study merit comment. Strengths include a contemporary, diverse, population-
based sample with a high response rate and specific measures of patients’ clinical decision 
making. Multiple imputation and weighting were used to account for potential bias related to 
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missing data, and to ensure that the results were representative of the overall population. 
Limitations include data obtained from 2 large SEER regions (Georgia and Los Angeles County), 
which might not reflect the entire US population. The number of patients who omitted 
radiotherapy is small. Patient responses are necessarily retrospective and may be subject to 
recall bias. Finally, our study evaluated patients’ views of radiotherapy omission, but did not 
explore views about omitting endocrine therapy rather than radiotherapy.39 Nonetheless, our 
study offers a novel and clinically relevant view of decision-making in older women with 
favorable prognosis breast cancer.  
 
In conclusio , our findings indicate several targets for interventions to improve the quality of 
older women’s decision-making in the context of radiotherapy after lumpectomy.  First, 
although decisions about radiotherapy omission are influenced by some clinical factors, 
interventions are necessary to ensure that decisions reflect not only considerations of age and 
tumor characteristics but also patients’ health status and remaining life expectancy. Second, 
communication must improve, as patients cannot share in the making of preference-
concordant decisions when they are not optimally informed about key facts such as recurrence 
risk and report that their providers had little discussion with them regarding this. Ultimately, we 
believe that a combination of physician-facing and patient-facing interventions are necessary, 
as it appears that both patients and physicians play important roles in the predominant 
intervention bias that has resulted in overtreatment of many older women with early stage 
breast cancer.7   Our results demonstrate that most older women with breast cancer care about 
avoiding complications and about avoiding worry about recurrence.  Therefore, decision aids 
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that present risk information in understandable formats, such as pictographs,40 constitute 
particularly promising avenues for the improvement of decision quality in practice.  Clear 
information and communication is critical, both for the subset of older patients with favorable 
risk disease in whom radiotherapy omission is a reasonable and guideline-concordant option if 
it accords with individual preferences, and also for the subset with more aggressive or 
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Figure 1: Odds ratios from a model estimating radiotherapy omission. Odds ratios from a 
multilevel logistic regression model estimating radiotherapy omission. The model was adjusted 
for race, income, education, insurance, marital status, BMI, and SEER site. The odds ratio for the 
surgeon effect represents the amount by which a patient’s odds of radiotherapy omission are 
multiplied if they see a surgeon associated with a rate of radiotherapy omission that is one 
standard deviation above the average surgeon.  
 
Figure 2: Patient-reported estimates of 10-year risk of local recurrence in patients aged 65-79 
with stage I, estrogen receptor positive invasive breast cancer compared to CALGB 9343 results. 
 
Figure 3. Patient reported reasons for omission of radiotherapy. Responses are not mutually 
exclusive. 
 
Figure 4. Patient reported considerations that influenced decisions about breast cancer 
treatment.  
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tTable 1: Patient Characteristics  
 No.  
(N=999) Weighted % % Omitting RT* P
†
 
Age      
65-69 410 40.2 5.4 <0.0001 
70-74 337 34.1 16  
75-79 252 25.7 26  
SEER Stage    0.5404 
1 749 73.5 14.3  
2 218 23.2 12.2  
Not reported 32 3.2 28.2  
ER status    0.0164 
Positive 857 85.5 15.3  
Negative 111 11.5 5.2  
Not reported 31 3.0 20.2  
SEER Grade    0.0029 
1 346 34.8 18.1  
2 430 43.4 14.4  
3 187 18.2 6.1  
Not reported 36 3.7 17.8  
Comorbidities    0.2995 
0 482 49.5 13.6  
1 315 30.3 12.8  
2+ 190 18.9 17.8  
Not reported 12 1.3 21.8  
Receipt of endocrine therapy
‡
    0.2222 
Yes 449 71.1 13.6  
No 170 26.8 17.7  
Not reported 15 2.1 18.5  
Site    0.0113 
Georgia 522 49.3 11.2  
Los Angeles County 477 50.7 17.2  
Primarily speak language other 
than English  
   0.1279 
Yes 896 90.9 13.5  
No 89 7.8 20.4  
Not reported 14 1.3 30.4  
Race    0.3019 
White 631 67.5 14.9  
Black 160 13.9 10.3  
Latina 136 11.3 14.9  
Asian 52 5.2 10.9  
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tOther, unknown, or missing 20 2.1 26.6  
Income     0.0265 
<20K 163 15.3 15.3  
20K - <40K 183 17.6 9.6  
40K - <60K 136 13.4 15.5  
60K - <90K 134 14.4 10.4  
90K+ 147 16.8 11.4  
Don’t know/not reported 236 22.6 21  
Education     0.5094 
At least some college 614 63.4 13.8  
No college 365 34.8 15.4  
Not reported 20 1.8 8.6  
Type of insurance     0.1035 
Medicaid 104 9.9 15.3  
Medicare 641 66.1 14.5  
Private 121 12.2 6  
Other 7 0.6 14.7  
Not reported 126 11.2 20.9  
Marital status     0.5347 
Married/partnered 523 53.3 13.5  
Not partnered 457 44.8 15  
Not reported 19 1.9 20.5  
BMI     0.1281 
 
Underweight (<18.5) 8 0.7 33.5  
Normal weight (18.5-25) 262 27.8 17.4  
Overweight (>25-30) 323 32.7 12.5  
Obese >30 371 35.7 12.7  
Not reported 35 3.2 18.4  
Bra cup size     0.5723 
A/B 289 29.0 15.9  
C 322 32.1 14.7  
D 197 19.7 13.3  
DD+ 156 15.8 11  
Not reported 35 3.4 17.1  




   0.5430 
≤30 minutes 350  11.3  
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t>30 minutes 126  11.3  Not reported 34  54.8  
*Percent omitting RT calculated within the weighted sample 
†
P values for differences in the proportion of RT omission; the ‘not reported’ category (if present) 
was excluded from the calculation. 
‡
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Figure 1: Odds ratios from a model estimating radiotherapy omission. Odds ratios from a multilevel logistic 
regression model estimating radiotherapy omission. The model was adjusted for race, income, education, 
insurance, marital status, BMI, and SEER site. The odds ratio for the surgeon effect represents the amount 
by which a patient’s odds of radiotherapy omission are multiplied if they see a surgeon associated with a 
rate of radiotherapy omission that is one standard deviation above the average surgeon.  
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Figure 2: Patient-reported estimates of 10-year risk of local recurrence in patients aged 65-79 with stage I, 
estrogen receptor positive invasive breast cancer compared to CALGB 9343 results.  
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Figure 3. Patient reported reasons for omission of radiotherapy. Responses are not mutually exclusive.  
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Figure 4. Patient reported considerations that influenced decisions about breast cancer treatment.  
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tOnline supplementary table 1: Physician Characteristics  
 No.*  
(N = 240) 
Weighted 
% 
Years in practice 
  0-10 yrs 
  11-20 
  ≥21 yrs 












  Georgia 







Work with residents and/or 
fellows 
  Yes 
  No 









Breast cancer volume within last 
12 months 
  ≤50 
  >50 











Surgeon involvement in RT 
decisions 
Not at all or slightly 
Somewhat 














*Number of surgeons who were linked to a patient in table 1 and 
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A12. Please tell us whether you have ever been told by a doctor that you had any of the following              
health conditions:   
  Yes    No  
  
a. Chronic bronchitis or emphysema 
  b. Heart disease, such as coronary artery disease or congestive heart failure 
  c. Diabetes 
  d. Blood clots in the legs or the lung 




  g. Depression 
  
h) High cholesterol 
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C1. Before your surgery, did you consult with any of these providers about your treatment decisions? 
Yes No  
  a) Radiation oncologist (a doctor who specializes in radiation treatment) 
  b) Medical oncologist (a doctor who specializes in chemotherapy) 
  
c) Plastic surgeon (a doctor who performs breast reconstruction) 
  d) Primary care provider (a doctor, physician assistant, or nurse practitioner who    
sees you for common problems or standard checkups) 
  e) Genetic counselor (someone who reviews your family history and explains the 
purpose and results of genetic tests) 
  f) Navigator (often a nurse, someone who helps you with your treatment schedule,  




C2.  What was the first surgery that you had to remove your breast cancer after the biopsy test? 
 
I did not have any surgery after the biopsy  
 
I had a mastectomy (removal of the entire breast)            
 
 



















. Did you have a second lumpectomy to remove more breast tissue from the same breast? 
       Yes – I had another lumpectomy to remove more breast tissue from the same breast 
       
No – I only had one lumpectomy 
 
b. Did you have a mastectomy later, on the same breast? 
Yes – I had a mastectomy after my lumpectomy 
 
No – I did not have a mastectomy 
             
c. How strongly did your doctor recommend that you have a mastectomy after your initial 
lumpectomy?  
     
 
Very strongly Strongly  Moderately Weakly Not at all 
 
d. How strongly did you request to have a mastectomy after your initial lumpectomy?  
     
 
Very strongly Strongly Moderately Weakly Not at all 
     
 
 
Please go to C3 at the top of 
the next page 
Please continue to C3 on the next page 
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C3.  What kind of mastectomy did you have?   
 I did not have a mastectomy 
 
Mastectomy only – no reconstruction 
 Mastectomy with reconstruction and I kept my own nipple, called a nipple sparing 
or nipple saving mastectomy 
  
Mastectomy with reconstruction and my original nipple was removed 
 
C4.  What type of breast reconstruction did you have? 
  I have not had any breast reconstruction surgery 
 
A DIEP flap, TRAM flap, or latissimus dorsi flap (uses your own tissue from the abdomen or back) 
 
An implant (silicone or saline) 
 












           
 
C6. How important were the following factors in your decision to have a mastectomy on both breasts? 
 










a. My age      
 
b. Having a family history of breast cancer 
     
 
c. Wanting both breasts to match after 





Please go to C7 at the 
top of the next page 
 
Please continue to C7 on the next page 
Go to C6 
below 
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C8.  At the time of your breast cancer diagnosis, how much time did it or would it have taken you to get 
from your home to the nearest radiation treatment facility?   
 
Less than 15 minutes 
 
31 to 60 minutes 
 
 
I don’t know  
15 to 30 minutes 
 
 
More than 60 minutes 
 
 
C9. Did any doctor tell you that radiation treatmentA 
 Yes        No Don’t remember 
a. Usually involves daily trips to an outpatient facility 
   
b. Can be completed in 3-4 weeks or less 




C14.  Did you or are you going to have radiation therapy to treat your breast cancer? 
    
Yes – I am finished 
with radiation therapy 
Yes – I am still having 
radiation therapy 
Yes – I plan to have radiation 


















Please answer the following questions even if you did not have radiation therapy 
C14a. Why didn’t you, or don’t you, plan to have radiation therapy?          
Please mark ALL that apply. 
My doctor(s) did not discuss it with me 
My doctor(s) said I didn’t need it 
My doctor(s) left it up to me and I chose not to 
I was worried about side effects or complications 
I was worried about the cost 
It would have been too much of a burden on me or my family 
Other (please explain): _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Please go to C18 on the next page 
Please go to C14a 
Please go to 
C15 below 
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C15. How many total weeks of radiation treatments are planned? 
    
1 week 2-4 weeks 5 weeks 6 or more weeks 
 
C16. How was, or will, your radiation treatment be given?  Please mark ALL that apply. 
    
Using beams from 
outside my body 
Using a balloon placed 
inside my breast 
Using needles placed 
into my breast 
I don’t know how my radiation 
treatment was, or will be, given 
 
C17. Which of the following areas were, or will be, treated with radiation?  Please mark ALL that apply. 
    
My whole breast Only the part of the breast 
where my tumor was 
The chest wall, after my 
mastectomy 







C20. Hormonal therapy helps block estrogen from getting to cancer cells that may remain in the body. 
Hormonal therapy is sometimes called “anti-estrogen therapy” or “endocrine therapy.” Examples include 
tamoxifen, anastrozole or Arimidex, letrozole or Femara, and exemestane or Aromasin.  
 
Have you or are you going to be taking any of these medications?  Please mark ONE. 
 
 Yes, I currently take one of these medications 
 Yes, I plan to take one of these medications in the future but haven’t started yet 
 Yes, I took one of these medications before but no longer take it  
 No, I am not taking any of these medications right now and I am unsure whether or not I 
should start 
 No, I have no plans to take any of these medications 
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Section D:  Decision Making 
D1. In general, please tell us how often you have these thoughts and feelings when you make decisions. 
 Never Rarely Sometimes Often Always 
a. I worry about making a bad decision 
     
b. I struggle to decide what the right decision is 
     
c. I get angry at myself when I have made a bad 
decision 
     
d. I worry a lot about the outcomes of my decisions 
     
 
D2.  When making decisions about how to treat my breast cancerA 
 Not     
at all  A little Somewhat 
Quite    
a bit A lot 
a. I weighed the pros and cons of all the treatment options 
     
b. I feel like I really thought through all the issues 
important to the treatment decisions 
    
 
c. I talked with others – family or friends – before making 
treatment decisions 
    
 
d. I talked with other breast cancer patients before making 
treatment decisions 
    
 
e. I spent time thinking about all of the treatment options 




D3.  When making decisions about how to treat my breast cancerA 








a. I would like to have had more information 
     
b. I would like to have participated more 
     
c. I am satisfied with the amount of time I had 
     
d. I am satisfied with the amount of involvement I had 
from family and friends  
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D4. When decisions were being made about your treatments, how important was it to you 
that your treatmentsA   
 










a. Reduced the need for more surgery 
     
b. Allowed you to avoid side effects of treatment 
     
c.  Allowed you to avoid exposure to radiation 
     
d. Required fewer trips back and forth for 
treatment visits 
     
e. Did not make you feel bad about your body 
     
f. Kept you from worrying about the cancer 
coming back 
     
g. Allowed you to feel feminine 
     
h. Were the most extensive possible 
     
i. Were the least extensive possible 
     
j. Allowed you to keep your original breast 
     
k. Were what your partner/family wanted you to do 
    
l. Were what your doctor wanted you to do  
     
m. Were the same treatments that other women 
you know have received 
     
n. Were the newest, most advanced treatments 
available  
     
o. Had the shortest recovery time 
     
p. Gave you peace of mind 
     
q. Allowed you to avoid having follow-up 
mammograms 
     
r. Did not require you to spend a lot of your own 
money 
     
s. Had a lower possibility of complications 
     
t. Allowed you to continue to care for your home 
and family 
     
u. Allowed you to continue to work for pay  
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D5. At the time that decisions were being made about your treatments, how much do you feel that                
your preferences were considered?  
   
  
 
Not at all Slightly Moderately Very much Completely 
 
Section E:  How You Feel About Your Decisions 
 
Please tell us how you feel about the decisions that were made for your breast cancer treatment.  If your doctor 
did not offer you the test or treatment that is listed, please mark N/A for “Not applicable.” 
 
 








e. Whether or not to have radiation therapy 
      
 
 





nor disagree Disagree 
Strongly 
Disagree 
d. The risk of my breast cancer coming back 
  





E3. How satisfied are you with the decision aboutA 
 










e. Whether or not to have radiation therapy 
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Quite a bit 
of the time 
All of  
the time 
H1. When it came to getting treatment for breast 
cancer, I preferred to be told what to do 
 
    
H2. When it came to getting treatment for breast              
cancer, I wanted my doctor to tell me what to do     
H3. I preferred to make my own decisions about my 





Section I: Your Thoughts and Feelings 
The questions below are important to help us better understand how women like you feel towards the end of 
treatment and the beginning of the recovery period.  Please answer these questions the best way you can. 
I1. For the question below, please write in a number from 0% to 100% whereA 
     0% = you think there is absolutely no chance that your breast cancer will 
come back in the breast or the area around it in the next 10 years, and 
 
100% = you think it is absolutely certain that your breast cancer will 
come back in the breast or the area around it in the next 10 years 
 
After receiving all the planned treatments, what do you think is the chance that your cancer will come back 




I2. After receiving all of the planned treatments, do you consider the chance of your cancer coming back in the 
breast or the area around it to be: 
     
Very low Low Moderate High Very high 
 
I3.  Next, we would like to ask you for your opinion on the chances of your cancer spreading to other parts of 
your body. For the question below, please write in a number from 0% to 100% whereA 
    0% = you think there is absolutely no chance that your breast cancer will 
spread to other parts of your body in the next 10 years, and 
 
100% = you think it is absolutely certain that your breast cancer will  
             spread to other parts of your body in the next 10 years 
 
After receiving all the planned treatments, what do you think is the chance that your cancer will           
spread to other parts of your body within 10 years? 
 
________ % (0 to 100) 
 
________ % (0 to 100) 
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I4. After receiving all the planned treatments, do you consider the chance of your cancer spreading to other 
parts of your body to be: 
     
Very low Low Moderate High Very high 
 
 
I5. How much did your doctors discuss with you the chance of your cancer coming back?  
     
Not at all A little bit Somewhat Quite a bit A lot 
 
 
I6. When your doctors discussed the chance of your cancer coming back, did they useA 
    
Only words 
(For example, “small chance”) 
Only numbers 
(For example, “8% chance”) 
Both words 
and numbers 
My doctors did not   




I7.  Compared to other women with similar breast cancer and treatment, how likely do you think it is that your 
breast cancer will come back? 
     
Much less likely Less likely About the same More likely Much more likely 
 
I8.  In the past month, how often have you worried about your cancer coming back?  
     
Almost never Rarely Sometimes Often Almost always 
 
I9.  During the past month, how often has worrying about your cancer coming backA 
 Almost 
never Rarely Sometimes Often 
Almost 
always 
a. Made you feel upset?  
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b. Made it difficult for you to carry out your usual 
daily activities at home or at work?   
 
  




I10.  When you see your cancer doctors for follow-up care, how often do they ask if you are worried about your 
breast cancer coming back? 
     




Section K:  Home and Work 
K15. How much do you worry about current or future financial problems as a result of your breast cancer       
and treatments? 
     
Not at all A little Somewhat Quite a bit A lot 
 
Section L: Language and Other Preferences 
L1.  What language do you primarily speak?  Please mark ONE. 
     English      Mandarin      Cantonese      Korean 
     Spanish      Vietnamese      Japanese                Other (please explain): _ _ _ _ _ _ _ _ _ 
    
 
L2. In general, what language(s) do you read and speak? 
     
Only English English better than 
any other language 
Both equally Another language 




L3. What language do you usually speak at home? 
     
Only English More English than 
any other language 
Both equally Another language 




L4. In what language do you usually think? 
     
Only English More English than 
any other language 
Both equally Another language 




L5. What language do you usually speak with your friends? 
     
Only English More English than Both equally Another language Only another 
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any other language more than English language 
 
 
Section M:  A Few More Questions 
 













M4. Before your breast surgery, what was your bra cup size? 
 
     A 
 
     D 
 
     B 
 
     DD 
 
     C 
 
     Other (please explain): _ _ _ _ _ _ _ _ _ _ 
M5. In the 12 months before your diagnosis with breast cancer, what was your experience with your 
menstrual periods? 
 
     I had no menstrual periods in the 12 months before my breast cancer diagnosis 
 
     I had regular (or the usual timing of) menstrual periods in the 12 months before my breast cancer 
diagnosis 
 
     I had a change in the timing of menstrual periods in the 12 months before my breast cancer diagnosis 
 
 
M6. In the 12 months before your breast cancer diagnosis, did you experience hot flashes or night sweats 









_____feet  _____inches     or     _____meters 
 
_______pounds     or     _______kilograms 
 
 
_______ / ________ / ____________ 
 month          day                year 
 
______ / _______ / ________ 
month        day           year 
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M8. When you were diagnosed with breast cancer, what was your marital status? 
 
     Married 
 
     Living with partner 
 
     Divorced 
 
     Widowed 
 
     Separated 
 
     Never married 
 
 
M9.  What is the highest level of education you have completed? 
 
     No high school 
 
     Some college or technical school 
 
     Some high school 
 
     College graduate (Bachelor’s degree) 
 
     High school graduate or G.E.D. 
 
     Graduate degree or higher 
 
M10.  Are you of Hispanic, Latino, or Spanish origin? 
 
     Yes, Mexican, Mexican-American, or Chicano 
 
     Yes, Puerto Rican 
 
     Yes, Cuban 
 
     Yes, another Hispanic, Latino, or Spanish origin (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 




M11.  Are you of Jewish descent?    
   











M13.  In what country were you born?  




M14.  In what country was your mother born?                 





_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
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M15. In what country was your father born?  







M16.  Which of the following best describes your race?  Please mark ALL that apply. 
 
     White 
 
     Chinese 
 
     Black or African-American  
 
     Filipino 
 
     American Indian or Alaska Native  
 
     Japanese 
 
     Native Hawaiian or other Pacific Islander  
 
     Korean 
 
     Asian Indian 
 
     Vietnamese 
 
     Other Asian (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
     Other Race (please explain): _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
Section N:  Your Doctors 
N1. We want to learn from doctors about better ways to communicate with patients and their families about 
treatment decisions. The information you provide below will help us contact the doctors who treat patients 
with breast cancer.  The doctors may be surveyed about their treatment practices.  Importantly, your 
answers will never be shared with any doctors and your personal information including your name will 
never be used in any communication. 
a. Surgeon who performed your first lumpectomy or mastectomy: 
Doctor’s last name:  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _  First name: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
Name of hospital or clinic:  _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
City: _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
 
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ 
_ 
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t Section A:  About You and Your Practice  A1. At how many hospitals do you see patients?   1 2 3 or more 
 
A2. Does your primary practice have 
 
 Yes No 
a. Residents and/or fellows   
b. Cancer care navigators for newly-diagnosed breast cancer 




A3. In the past 12 months, approximately what percentage (%) of your new patients were  
 
a.  ______ % Breast cancer (including DCIS) patients     
b.  ______ % Other (non-breast) oncology patients 
c.  ______ % Patients without cancer 
     100    %  Total for the past 12 months 
A4.  In the past 12 months, how many new patients who were diagnosed with breast cancer have you seen?  
(Please include patients who came to you for a second opinion.) 
      None       11 – 20         51 – 100  
      1 – 10       21 – 50         More than 100 
 
A5.  In the past 12 months, approximately what percent of your newly diagnosed breast cancer patients did 
you discuss in a multidisciplinary meeting (e.g., a tumor board) to get input on the treatment plan? 
 
     0% 
 
     10 – 25% 
 
    More than 50% 





Section I:  Radiation Therapy 
 
 
I3.  How involved are you in the selection of adjuvant radiation therapy approach in your                              
post-lumpectomy patients? 
     


















Page 49 of 51 Cancer












Section L:  A Few More Questions 
 










L3. How old are you?     _______ years 
 




L5. Which of the following best describes your race?  Please mark ALL that apply.  
     White      Chinese 
     Black or African-American       Filipino 
     American Indian or Alaska Native       Japanese 
     Native Hawaiian or other Pacific Islander      Korean 
     Asian Indian      Vietnamese 
     Other Asian (please explain):  _ _ _ _ _ _ _ _ _ _ _ _ __ _ _ _ _ _ _ _ _ _ _ _ _ _ 















L2. Please PRINT the name of the 
location where you practice the most: ___________________________________________________ 
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M3. Which radiation oncologists do you interact with the most when you are uncertain about the 
management of your newly diagnosed patients with breast cancer?  Please PRINT the                  
first and last names of up to 2 radiation oncologist whom you would approach to get advice. 
 
Name Hospital / Institution / Practice 
Do you share 
patients via a 
tumor board? 
Yes      No 
 
__________________________________ ________________________________   
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